drugset / Trial / NCT00000142
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
Phase 2/3
Completed
64 enrolled
Johns Hopkins Bloomberg School of Public Health
Baylor College of Medicine · collabIcahn School of Medicine at Mount Sinai · collabJohns Hopkins University · collabLouisiana State University Health Sciences Center in New Orleans · collabNYU Langone Health · collabNew Jersey Medical School · collabNorthwestern University · collabUniversity of California, Los Angeles · collabUniversity of California, San Diego · collabUniversity of California, San Francisco · collabUniversity of Miami · collabUniversity of North Carolina, Chapel Hill · collabUniversity of South Florida · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.
Timeline
- Start
- 1994-04
- Primary completion
- 1996-02
- Completion
- 1996-02
Publications
- Background Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med. 1997 Feb 15;126(4):264-74. doi: 10.7326/0003-4819-126-4-199702150-00002.
- Background Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. AIDS. 2000 Jul 28;14(11):1571-81.
- Background Kravcik S. Cidofovir for cytomegalovirus retinitis. Ann Intern Med. 1997 Sep 15;127(6):490-1. doi: 10.7326/0003-4819-127-6-199709150-00015. No abstract available.
- Holland GN, Van Natta ML, Goldenberg DT, Ritts R Jr, Danis RP, Jabs DA; Studies of Ocular Complications of AIDS Research Group. Relationship Between Opacity of Cytomegalovirus Retinitis Lesion Borders and Severity of Immunodeficiency Among People With AIDS. Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1853-1862. doi: 10.1167/iovs.18-26517.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIDOFOVIR ANHYDROUS | Small molecule | 3 mg/kg | Intravenous |
| Subject | CIDOFOVIR ANHYDROUS | Small molecule | 5 mg/kg | Intravenous |